|Bid||1,789.80 x 0|
|Ask||1,789.80 x 0|
|Day's range||1,751.40 - 1,793.00|
|52-week range||1,215.83 - 2,726.53|
|Beta (5Y monthly)||0.29|
|PE ratio (TTM)||1,775.25|
|Earnings date||27 Jul 2022|
|Forward dividend & yield||0.75 (4.25%)|
|Ex-dividend date||19 May 2022|
|1y target est||1,805.24|
PHILADELPHIA, June 29, 2022--GSK selects Target the Future grant recipient in innovation challenge supporting multiple myeloma community
GlaxoSmithKline (GSK) closed the most recent trading day at $43.35, moving -0.8% from the previous trading session.
Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.